Credit: Getty Images. The FDA has approved the GSP Neonatal Creatine Kinase-MM kit for use in screening newborns for Duchenne Muscular Dystrophy. The Food and Drug Administration (FDA) has approved ...
Dyne launched a global clinical trial, FORZETTO, to test its exon-skipping therapy z-rostudirsen in boys with Duchenne ...
Duchenne muscular dystrophy (DMD) is a genetic disease that causes muscle weakness and motor skill difficulties due to the loss of muscle tissue from changes to dystrophin proteins. It mostly affects ...
Pfizer is getting back to work on a late-stage test for its Duchenne muscular dystrophy (DMD) gene therapy. The decision comes several months after a patient death in a phase 1 trial drew a clinical ...
The X-linked neuromuscular disorder Duchenne muscular dystrophy (DMD), which historically has been diagnosed in boys between the ages of 3 and 6 years, has become an important candidate for newborn ...
Duchenne muscular dystrophy (DMD) is a genetic condition that causes progressive muscle weakness and wasting. It is an X-linked recessive disorder that occurs due to changes in the DMD gene, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results